Our Mission:

The Healing Advocacy Fund is a nonprofit organization dedicated to supporting the thoughtful and effective development, implementation, and education of the nation's first regulated psilocybin therapy program, which Oregon voters passed through Measure 109 in November 2020.
Measure 109
Recap
Oregonians Are Suffering Now, More Than ever

1. According to a recent survey conducted by CDC’s National Center for Health Statistics and the Census Bureau: At the start of quarantine, 1 in 5 Americans were experiencing symptoms of clinical anxiety or depression, but now over a third of Americans say they are experiencing symptoms amid the country’s coronavirus pandemic.

2. Here in Oregon, the mental health crisis is even more acute. According to Mental Health America, Oregon’s mental health crisis is the most severe in the country, and that was before the pandemic hit.
Psilocybin Research

- Rigorous studies at the leading medical research institutions such as Johns Hopkins, UCLA, University of Alabama and NYU show that psilocybin works. It is uniquely effective in treating depression, end-of-life anxiety, and addiction.
- It shows so much promise the FDA recently granted it a “breakthrough therapy” designation - meaning that it may demonstrate substantial improvement above and beyond what is currently available.
The Measure
M 109: A measured approach

**GOAL:** Create licensing and regulatory framework to serve those who seek Psilocybin Therapy and could safely benefit from it.
What Measure 109 Does

- Establishes a regulatory framework within the Oregon Health Authority (OHA) that will allow trained practitioners to administer psilocybin services at specially licensed centers
- Establishes the Oregon Psilocybin Advisory Board, appointed by the Governor
- Imposes a two-year development period before initial licenses are granted
- Requires the establishment of a training and licensure system for psilocybin facilitators, psilocybin manufacturers, and testing labs
- Requires the establishment of a tracking system for psilocybin products
M 109 does NOT allow:

- Retail sales
- Off-site consumption or possession
- Branding or advertising
- Unregulated or untracked psilocybin production, delivery, or inventory
- Service centers in residential neighborhoods or near a school
- Access for minors
Psilocybin Services
A Four Step Process
The Oregon Model delivers psilocybin services in a four-step process:

1. **Assessment**: Participants complete a screening process and match with a psilocybin facilitator based on individual needs and fit.

2. **Intention-Setting**: Facilitator meets with participant for a preparation session to explain the process, incorporate participant goals, and develop an individualized safety plan.

3. **Administration Session**: Psilocybin is administered at a licensed service center by a trained facilitator, who oversees the session and supports the participant throughout.

4. **Integration Session**: Participant meets with their facilitator to integrate insights and learning from the psilocybin experience into daily life.
Implementation
Overview

- Measure 109 establishes an initial **two-year development period**.
- During that period, the Oregon Health Authority, **with the guidance of an Advisory Board**, will study psilocybin research and science and develop a regulatory program, including **rules, training requirements, and licensing requirements**.
- In January 2023, at the completion of the two-year study period, OHA will begin accepting applications and issuing licenses to:
  - **Facilitate** psilocybin service administration sessions,
  - **manufacture** psilocybin products,
  - **operate** psilocybin service centers, and
  - **facilitate** psilocybin therapy services.
Governor appoints 14-16 members

Duties of the board:
- Collect existing studies
- Recommend guidelines for serving clients and licensing facilitators, service centers, etc.
- Establish public safety standards
- Establish professional conduct, certification, and training requirements
- Develop a long-term strategic plan for ensuring that psilocybin services will be accessible and affordable therapeutic option
- Monitor and study federal law, attempt to work with federal gov
- Can establish subcommittees
Psilocybin Advisory Board Members

- **Public Health Director Designee:** Andre Ourso, OHA
- **State Health Officer Designee:** Dr. Tom Jeanne, OHA
- **Oregon Health Policy Board Designee:** Barb Hansen
- **State Employee w/ Public Health Expertise:** Ali Hamade, OHA
- **Local Health Officer:** Dr. Sarah Present, Clackamas County
- **Addictions Medicine Specialist:** Kevin Fitts, Portland
- **Licensed Psychologist:** Dr. Kimberly Golletz, Corvallis
- **Licensed Physician:** Dr. Todd Korthuis, OHSU
- **Tribal Representative:** Angie Butler

- **Academic Researcher:** Dr. Chris Stauffer, Portland
- **Mycologist:** Dr. Jessie Uehling, Oregon State University
- **Hard Reduction Specialist:** Dr. Angela Carter, Portland
- **Psychopharmacological Specialist:** Dr. Athier Abbas, OHSU
- **OLCC:** Nathan Rix
- **Oregon DOJ:** David Hart
- **Member of the Public:** Steph Barrs, Bend
- **Member of the Public:** Dr. Rachel Knox, Portland
Implementation Timeline

**Jan. 1st, 2020**
Psilocybin Advisory Board application process closes

**Dec. 2020**
Psilocybin Advisory Board application process opens

**Jan. 19th 2021**
Legislative session begins

**Feb. 2021**
Governor makes appointments to Advisory Board

**Mar. 2021**
Advisory Board’s first meeting

**June 2021**
Advisory Board reports science and research findings

**June 2022**
Advisory Board makes recommendations for rules and regulations

**July 2021**
OHA publishes psilocybin science and research

**Dec. 2022**
OHA adopts rules and regulations

**Jan. 2023**
OHA begins accepting license applications
Local Control
Overview

What powers does Measure 109 provide for local governments?

1. **Opt-in** by adopting reasonable time, place, and manner (TPM) regulations
2. **Take no action** and default to state regulations
3. **Opt-out** by sending the question to residents at the next general election
Questions?

Sam Chapman
Executive Director
Sam@healingadvocacyfund.org

Thank You